285 related articles for article (PubMed ID: 18586273)
1. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression.
Keitner GI; Garlow SJ; Ryan CE; Ninan PT; Solomon DA; Nemeroff CB; Keller MB
J Psychiatr Res; 2009 Jan; 43(3):205-14. PubMed ID: 18586273
[TBL] [Abstract][Full Text] [Related]
2. Risperidone for treatment-refractory major depressive disorder: a randomized trial.
Mahmoud RA; Pandina GJ; Turkoz I; Kosik-Gonzalez C; Canuso CM; Kujawa MJ; Gharabawi-Garibaldi GM
Ann Intern Med; 2007 Nov; 147(9):593-602. PubMed ID: 17975181
[TBL] [Abstract][Full Text] [Related]
3. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
5. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
[TBL] [Abstract][Full Text] [Related]
7. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.
Cusin C; Iovieno N; Iosifescu DV; Nierenberg AA; Fava M; Rush AJ; Perlis RH
J Clin Psychiatry; 2013 Jul; 74(7):e636-41. PubMed ID: 23945458
[TBL] [Abstract][Full Text] [Related]
9. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu JH; Kujawa MJ; Mahmoud R; Gharabawi GM
J Affect Disord; 2009 Nov; 118(1-3):139-46. PubMed ID: 19321206
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
Calabrese JR; Keck PE; Macfadden W; Minkwitz M; Ketter TA; Weisler RH; Cutler AJ; McCoy R; Wilson E; Mullen J
Am J Psychiatry; 2005 Jul; 162(7):1351-60. PubMed ID: 15994719
[TBL] [Abstract][Full Text] [Related]
12. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
Furey ML; Drevets WC
Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.
Reeves H; Batra S; May RS; Zhang R; Dahl DC; Li X
J Clin Psychiatry; 2008 Aug; 69(8):1228-1236. PubMed ID: 18681749
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
Liebowitz MR; Yeung PP; Entsuah R
J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression.
Bauer M; Bschor T; Kunz D; Berghöfer A; Ströhle A; Müller-Oerlinghausen B
Am J Psychiatry; 2000 Sep; 157(9):1429-35. PubMed ID: 10964859
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
Smith EG; Deligiannidis KM; Ulbricht CM; Landolin CS; Patel JK; Rothschild AJ
J Clin Psychiatry; 2013 Oct; 74(10):966-73. PubMed ID: 24229746
[TBL] [Abstract][Full Text] [Related]
18. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
[TBL] [Abstract][Full Text] [Related]
19. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.
Hirschfeld RM; Keck PE; Kramer M; Karcher K; Canuso C; Eerdekens M; Grossman F
Am J Psychiatry; 2004 Jun; 161(6):1057-65. PubMed ID: 15169694
[TBL] [Abstract][Full Text] [Related]
20. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.
Madhoo M; Keefe RS; Roth RM; Sambunaris A; Wu J; Trivedi MH; Anderson CS; Lasser R
Neuropsychopharmacology; 2014 May; 39(6):1388-98. PubMed ID: 24309905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
